RxDoctor Payments Data

Pedro Arrazola, MD

Internal Medicine · McAllen, TXNPI 1730296252

Payments from drug & device makers

$1,270in general payments, 2019–2025

Across 68 payments — averaging $18.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Otsuka America Pharmaceutical, Inc.$280
  • Novo Nordisk$213
  • Smith+Nephew$144
  • AstraZeneca$119
  • Dexcom, Inc.$93
  • Johnson & Johnson$82
  • plus $340 from 9 others

What the payments were for

  • Food & beverage$1,270100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,270 in reported general payments places this provider in the 70th percentile of 7,675 internal medicine providers in Texas.

See all internal medicine providers in Texas

Medicare billing

Part B allowed, 2024
$122,346
Medicare patients
166
Services billed
3,801

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide262$316,872
EliquisApixaban132$103,747
MounjaroTirzepatide73$76,161
MyrbetriqMirabegron88$66,090
JardianceEmpagliflozin103$58,024
LinzessLinaclotide57$55,838
JanuviaSitagliptin Phosphate64$49,691
Invega SustennaPaliperidone Palmitate11$41,340
FarxigaDapagliflozin Propanediol35$27,121
EntrestoSacubitril/Valsartan19$23,271
ProliaDenosumab13$21,184
TradjentaLinagliptin29$18,702
CreonLipase/Protease/Amylase11$15,274
Diclofenac Sodium ErDiclofenac Sodium157$14,371
XareltoRivaroxaban18$13,121

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$213$316,872262 claims
Lilly USA, LLCMounjaro$79$76,16173 claims
AbbVieLinzess, Creon$28$71,11268 claims
Johnson & JohnsonInvega Sustenna, Xarelto$82$54,46129 claims
AstraZenecaFarxiga$119$27,12135 claims
Sumitomo Pharma America, Inc.Gemtesa$67$7,55624 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 7,675 internal medicine providers in Texas.

Other internal medicine in McAllen

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →